CytoMed Therapeutics (US:GDTC)2023-04-30 16:00Financial Performance - As of December 31, 2022, the company reported accumulated losses of S$8.20 million, with net cash used in operating activities amounting to S$1.40 million[631]. - The company had cash and cash equivalents of S$1.58 million as of December 31, 2022, down from S$2.51 million in 2021[632]. - Net cash used in investing activities for 2022 was S$473,305, primarily due to the purchase of property, plant, and equipment[638]. - The company generated S$968,716 from financing activities in 2022, mainly from the issuance of ordinary shares totaling S$1.22 million[641]. Future Outlook - The company expects significant increases in expenses and capital requirements as it continues R&D activities and seeks regulatory approvals for product candidates[631]. - The company plans to fund its operations through various sources, including loans, equity, and debt financings[632]. - The company has contractual obligations totaling S$2.16 million, with S$1.83 million related to convertible bonds due within one year[647]. - The company has not yet commercialized any product candidates and does not expect to generate revenue from commercial sales in the foreseeable future[630]. Research and Development - The company is conducting the ANGELICA Trial with National University Hospital Singapore as part of its ongoing R&D efforts[642]. - The company estimates accrued R&D expenses based on known facts and circumstances, with no material adjustments to prior estimates reported to date[653]. Company Classification - The company is classified as an "emerging growth company" and has opted for delayed adoption of certain accounting standards[659]. - The company will maintain its emerging growth status until it exceeds U.S.$1.235 billion in annual revenue or meets other specified criteria[660]. Shareholder Actions - On April 21, 2023, the mDR Convertible Loan was converted into 589,509 ordinary shares at approximately U.S.$1.89774 per share[661].